title: Distribution of arylamine N-acetyltransferase 2 (nat2) genotypes among Omanis.
abstract: OBJECTIVE
  to determine the genotypes of arylamine N-acetyltransferase (NAT2) among 127 unrelated apparently healthy Omanis.
  
  
  METHODS
  Identify the most common known polymorphisms of NAT*2 gene namely, G(191)A, C(282)T, C(341)T, C(481)T, G(590)A, A(803)G and G(857)A using PCR-RFLP analysis.
  
  
  RESULTS
  Eleven allele variants (3 alternative) and 30 different genotypes were determined. The commonest alleles were found to be NAT*5B, NAT2*6A and NAT*4 with corresponding frequencies of 0.362, 0.248 and 0.189 respectively. The overall frequency of rapid acetylator alleles was 0.25.
  
  
  CONCLUSIONS
  A new allele variant containing G(590)A, C(282)T and T(341)C polymorphisms was found in one subject (was named NAT2*5J). The commonest genotypes were found to be 5B/5B, 5B/6A, 4/5B, 4/6A with frequencies 0.165, 0.157, 0.118, 0.110 and 0.079 respectively.
authors.affiliation: Departments of Pharmacology and.
authors.forename: Musbah O M
authors.initials: MO
authors.lastname: Tanira
authors.forename: Mehmet
authors.initials: M
authors.lastname: Simsek
authors.forename: Khalid
authors.initials: K
authors.lastname: Al Balushi
authors.forename: Khulood
authors.initials: K
authors.lastname: Al Lawatia
authors.forename: Hameedah
authors.initials: H
authors.lastname: Al Barawani
authors.forename: Riad A
authors.initials: RA
authors.lastname: Bayoumi
keywords: N-acetyltransferase (NAT2); Omani; genotyping
references.citation: Toxicol Lett. 2000 Mar 15;112-113:349-56
references.pmid: 10720751
references.citation: Pharmacogenetics. 1997 Jun;7(3):187-91
references.pmid: 9241658
references.citation: Pharmacogenetics. 1995 Feb;5(1):1-17
references.pmid: 7773298
references.citation: Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):29-42
references.pmid: 10667461
references.citation: Am J Hum Genet. 1995 Sep;57(3):581-92
references.pmid: 7668286
references.citation: Pharmacogenetics. 1995 Apr;5(2):64-71
references.pmid: 7663530
references.citation: Clin Pharmacol Ther. 1999 May;65(5):519-25
references.pmid: 10340917
references.citation: Mutat Res. 2002 Sep 30;506-507:65-77
references.pmid: 12351146
references.citation: Trends Pharmacol Sci. 1999 Aug;20(8):342-9
references.pmid: 10431214
references.citation: Toxicol Lett. 1998 Dec 28;102-103:155-60
references.pmid: 10022248
references.citation: Clin Chem. 2001 Jan;47(1):134-7
references.pmid: 11148192
references.citation: J Clin Invest. 1998 Oct 15;102(8):1534-9
references.pmid: 9788966
references.citation: Drug Metab Dispos. 1999 Sep;27(9):957-9
references.pmid: 10460790
references.citation: Pharmacogenetics. 1997 Feb;7(1):73-82
references.pmid: 9110365
references.citation: Clin Genet. 1999 Oct;56(4):247-58
references.pmid: 10636440
references.citation: Clin Biochem. 2000 Oct;33(7):585-8
references.pmid: 11124345
references.citation: Carcinogenesis. 1996 Sep;17(9):1923-9
references.pmid: 8824515
references.citation: Pharmacogenetics. 2000 Feb;10(1):79-83
references.pmid: 10739175
references.citation: Drug Metab Rev. 1999 May;31(2):489-502
references.pmid: 10335449